New York, NY -- (SBWIRE) -- 12/16/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Opko Health Inc.(NYSE:OPK), CytRx Corporation (NASDAQ:CYTR), Coronado Biosciences Inc (NASDAQ:CNDO), Sprint Corporation (NYSE:S)
Opko Health Inc.(NYSE:OPK) showed a volume of 20.21 million shares by the end of last trade whereas the average volume of the stock remained 5.07 million shares. The stock opened the session at $9.47 but then moved to $8.97. At that price, the stock showed a negative performance of -4.78%. OPKO Health, Inc. (OPKO) is a multi-national pharmaceutical and diagnostics company. OPKO is developing a range of solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, point-of-care tests, and pharmaceuticals and vaccines. Its lead program is a molecular diagnostics platform for the development and commercialization of blood-based tests for conditions.
Will OPK Get Buyers Even After The Recent Rally? Find Out Here
CytRx Corporation (NASDAQ:CYTR) opened the session at $6.17 and closed the session at $5.72. The stock showed a negative performance of -6.54% in previous trading session. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate.
Has CYTR Found The Bottom And Ready To Gain Momentum? Find Out Here
Coronado Biosciences Inc (NASDAQ:CNDO) opened the session at $2.44 and closed the session at $2.15. The stock showed a positive performance of 20.79% in previous trading session. Traded with volume of 19.27 million shares in the prior session and the average volume of the stock remained 2.10 million shares. Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company’s two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm,
Why Should Investors Buy CNDO After The Recent Gain? Just Go Here and Find Out
Sprint Corporation (NYSE:S) the stock advanced 3.44% and finished the session at $8.43. Traded with volume of 19.44 million shares in the prior session and the average volume of the stock remained 19.04 million shares.
Will Sprint Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)